Rina Kansal | Medicine and Dentistry | Best Researcher Award

Rina Kansal | Medicine and Dentistry | Best Researcher Award

University at Buffalo | United States

Dr. Rina Kansal, M.D., is an accomplished physician-scientist with extensive expertise in molecular oncology, genetics, and hematopathology. She has served in diverse academic and clinical leadership roles at prestigious institutions including the University of Michigan, SUNY Buffalo, Medical College of Wisconsin, Cedars-Sinai Medical Center, Pennsylvania State University, and the Versiti Blood Center of Wisconsin. Over her career, Dr. Kansal has combined clinical practice, laboratory diagnostics, and academic teaching with a strong emphasis on advancing precision medicine. Her contributions span across hematopathology, molecular pathology, and genetic testing, where she has played a pivotal role in integrating cutting-edge diagnostics into patient care. In addition to her clinical leadership, she has maintained continuous scholarly activity aimed at enhancing medical education and translational research. With certifications from the American Board of Pathology and the American Board of Medical Genetics and Genomics, she exemplifies a career committed to advancing pathology and medical education.

Publication Profile

Orcid

Education

Dr. Kansal’s medical education began at Maulana Azad Medical College, University of Delhi, India, where she earned her M.B.B.S. degree. She further strengthened her global qualifications by completing the Professional and Linguistic Assessment Board Examination in the U.K. and achieving M.R.C.P. Part 1 certification in Internal Medicine from the Royal College of Physicians, Edinburgh. After immigrating to the United States, she successfully cleared USMLE Steps 1 and 2, becoming certified by the Educational Commission for Foreign Medical Graduates. She completed her residency in Anatomic and Clinical Pathology at SUNY Buffalo and pursued advanced fellowships in oncologic pathology (Roswell Park Cancer Institute, hematopathology (University of Michigan, and molecular genetic pathology (UCLA. She is diplomate of the American Board of Pathology in Anatomic, Clinical, and Hematologic Pathology and holds certification in Molecular Genetic Pathology. she completed Medical Education Research Certification through the AAMC.

Experience

Dr. Kansal’s professional journey spans several decades, integrating academic, clinical, and administrative excellence. She began as an Instructor of Anatomy at Maulana Azad Medical College before transitioning to the United Kingdom as a Senior House Officer and Registrar. In the U.S., she advanced through residency and faculty positions, becoming Assistant Professor at SUNY Buffalo and later Director of Hematopathology and Flow Cytometry at the Medical College of Wisconsin. She gained further experience at Cedars-Sinai Medical Center as Staff Hematopathologist and Visiting Scientist. At Penn State Hershey Medical Center, she served as Associate Professor of Pathology before joining Versiti Blood Center of Wisconsin as Associate Medical Director of Molecular Oncology and Genetics. She has dedicated herself to scholarly pursuits, preparing for academic faculty advancement. Across these roles, she has contributed to medical education, research, and diagnostic innovation, mentoring students and improving laboratory practices.

Honors and Awards

Dr. Kansal’s distinguished career is marked by numerous certifications and recognitions reflecting her clinical expertise and commitment to lifelong learning. She is board-certified in Anatomic Pathology, Clinical Pathology, Hematopathology, and Molecular Genetic Pathology, with certifications spanning  through. Her global qualifications include medical certifications in India, the United Kingdom, and the United States, demonstrating her international professional standing. She holds the Membership of the Royal College of Physicians (M.R.C.P.), certification from the General Medical Council (U.K.), and American Board diplomate status. Additionally, she earned the Medical Education Research Certification (MERC) from the American Association of Medical Colleges, underscoring her dedication to advancing medical pedagogy. While her formal accolades are primarily board certifications and professional recognitions, her honors are also reflected in the senior academic and leadership positions she has held across prominent medical schools and healthcare institutions, where she has been consistently recognized for her expertise and contributions.

Research Focus

Dr. Kansal’s research focus lies at the intersection of molecular oncology, hematopathology, and precision diagnostics. Her work emphasizes the use of molecular genetic pathology to better understand and classify hematologic malignancies, solid tumors, and genetic disorders. Through her clinical and research roles, she has explored applications of molecular techniques such as cytogenetics, flow cytometry, and next-generation sequencing in diagnosing complex cancers. At UCLA, during her fellowship and subsequent research year, she contributed to advancing molecular diagnostics and translational research in cancer genomics. Her scholarly pursuits also extend into medical education research, reflected in her MERC certification, aiming to improve teaching methodologies for pathology and laboratory medicine. With expertise spanning multiple sub-specialties of pathology, Dr. Kansal has consistently worked to bridge laboratory innovations with clinical outcomes. Her ongoing academic interests include expanding the role of genomic testing in personalized medicine and integrating evidence-based approaches into pathology education and practice.

Publications

  • Research Progress in Hematological Malignancies: A Molecular Genetics Perspective

  • Rapid Whole-Genome Sequencing in Critically Ill Infants and Children with Suspected, Undiagnosed Genetic Diseases: Evolution to a First-Tier Clinical Laboratory Test in the Era of Precision Medicine

  • Is It Time to Assess T Cell Clonality by Next-Generation Sequencing in Mature T Cell Lymphoid Neoplasms? A Scoping Review (Journal of Molecular Pathology)

  • The Placement of Auer Rods as a Single Diagnostic Criterion for the Highest-Risk Category of Myelodysplastic Syndromes: A Single-Institution Study and Critical Analysis

  • The CRISPR-Cas System and Clinical Applications of CRISPR-Based Gene Editing in Hematology with a Focus on Inherited Germline Predisposition to Hematologic Malignancies

Conclusion

In conclusion, Dr. Rina Kansal stands as a highly accomplished physician, educator, and researcher with an exceptional record of achievement in pathology, molecular genetics, and oncology. Her career trajectory, spanning continents and premier academic institutions, reflects her adaptability and dedication to advancing patient care through innovation in diagnostics and medical education. With board certifications in multiple sub-disciplines of pathology and extensive experience in both clinical practice and research, she has continually contributed to the evolution of precision medicine. Her educational achievements, professional leadership roles, and continuous pursuit of scholarly activities underscore her commitment to excellence. Beyond her clinical and academic expertise, Dr. Kansal’s focus on teaching, mentoring, and advancing medical education distinguishes her as a leader preparing the next generation of pathologists. Her career exemplifies the integration of scientific rigor, clinical expertise, and dedication to advancing healthcare through research, diagnostics, and education.

Fabio Artosi | Medicine and Dentistry | Young Scientist Award

Fabio Artosi | Medicine and Dentistry | Young Scientist Award

Università degli Studi di Roma|Italy

Dr. Fabio Artosi is an accomplished medical doctor, dermatologist, and researcher whose career spans clinical medicine, oncology, and translational dermatology. He demonstrated academic excellence early, graduating from the State Classical High School “Piero Gobetti” with top honors. He pursued a single-cycle Master’s degree in Medicine and Surgery at Tor Vergata University of Rome, achieving the highest grade with honors. His thesis on unknown-primary melanoma won the “Silvio Pisotre” award for best dermatology thesis. Licensed as a medical doctor and registered in the Province of Latina, Dr. Artosi embarked on a trajectory combining patient care, postgraduate research, and innovation in dermatology. He has held competitive scholarships in Medical Oncology (Federico II University of Naples) and Dermatology and Venereology (Tor Vergata University). Currently a PhD candidate in Medical-Surgical Biotechnologies and Translational Medicine, he is deeply engaged in real-world studies, clinical trials, and experimental research focusing on skin cancer, inflammatory dermatoses, and targeted biological therapies. Author of numerous peer-reviewed articles, he actively contributes to international conferences, delivering oral presentations on advanced therapeutic strategies. With a commitment to integrating scientific discovery into patient care, Dr. Artosi stands at the forefront of dermatological innovation, blending academic rigor with compassionate clinical practice.

Publication Profile

Artosi, Fabio – Author details – Scopus Preview

Education

Dr. Fabio Artosi completed his secondary education at the State Classical High School “Piero Gobetti” in Fondi, Italy, graduating with a diploma awarded with full marks, a testament to his excellence in humanities, languages, and analytical thinking. He then pursued his studies at the Tor Vergata University of Rome, where he obtained a single-cycle Master’s degree in Medicine and Surgery with the highest honors, earning praise for his experimental thesis on the characterization of unknown-primary melanoma in light of new therapeutic options, a multicenter study that combined rigorous research methodology with clinical application. Shortly after, he achieved his national medical license and was registered with the Medical Doctors’ Register of the Province of Latina. His postgraduate path began with a scholarship in Medical Oncology at the Federico II University of Naples, where he refined his expertise in the clinical management of oncological patients. He was subsequently selected for the specific training course in General Medicine, further broadening his clinical scope. Continuing his specialization, he received a postgraduate scholarship in Dermatology and Venereology at Tor Vergata University, where he remains actively engaged. Currently, as a PhD student in Medical-Surgical Biotechnologies and Translational Medicine, he focuses on experimental dermatology, translational oncology, and epidemiology, integrating research excellence with patient-centered car.

Experience

Dr. Artosi’s career integrates direct patient care with high-impact research. Following his medical qualification in 2020, he undertook a postgraduate scholarship in Medical Oncology at Federico II University of Naples, where he gained advanced clinical skills in tumor diagnosis, systemic therapies, and patient follow-up.He entered the General Medicine training program while securing a dermatology scholarship at Tor Vergata University, immersing himself in the management of complex dermatological cases including autoimmune, inflammatory, and neoplastic skin diseases.He has been actively involved in multicenter clinical trials on biologics, immunotherapies, and targeted dermatological treatments, contributing to studies on psoriasis, hidradenitis suppurativa, actinic keratosis, chronic urticaria, and skin cancer prevention. His clinical expertise is complemented by strong dermoscopic, histopathological, and research protocol development skills. Internationally recognized for his scientific contributions, Dr. Artosi has presented at major dermatology and oncology conferences, including SIDEMAST and ADOI congresses, often as an invited speaker. His research output covers both real-life clinical studies and translational investigations into molecular biomarkers, immune modulation, and drug response patterns. Currently, as a PhD researcher, he continues to merge clinical insights with laboratory innovation, aiming to improve therapeutic strategies and patient outcomes in dermatology and related fields.

Honors and Awards

Dr. Fabio Artosi completed his secondary education at the State Classical High School “Piero Gobetti” in Fondi, Italy, graduating with a diploma awarded with full marks, a testament to his excellence in humanities, languages, and analytical thinking. He then pursued his studies at the Tor Vergata University of Rome, where he obtained a single-cycle Master’s degree in Medicine and Surgery with the highest honors, earning praise for his experimental thesis on the characterization of unknown-primary melanoma in light of new therapeutic options, a multicenter study that combined rigorous research methodology with clinical application. Shortly after, he achieved his national medical license and was registered with the Medical Doctors’ Register of the Province of Latina. His postgraduate path began with a scholarship in Medical Oncology at the Federico II University of Naples, where he refined his expertise in the clinical management of oncological patients. He was subsequently selected for the specific training course in General Medicine, further broadening his clinical scope. Continuing his specialization, he received a postgraduate scholarship in Dermatology and Venereology at Tor Vergata University, where he remains actively engaged. Currently, as a PhD student in Medical-Surgical Biotechnologies and Translational Medicine, he focuses on experimental dermatology, translational oncology, and epidemiology, integrating research excellence with patient-centered care.

Research Focus

Dr. Artosi’s research lies at the intersection of dermatology, oncology, and translational medicine. His primary interests include the epidemiology, pathogenesis, and clinical management of skin cancers (both melanoma and non-melanoma), with an emphasis on prevention strategies, biomarker discovery, and personalized treatment. He has contributed significantly to studies evaluating biologic agents in psoriasis, hidradenitis suppurativa, and psoriatic arthritis, particularly in complex cases with metabolic or oncological comorbidities. A key part of his work addresses inflammatory skin disorders, integrating insights from immunology to optimize biologic and small-molecule therapy outcomes. He is also involved in real-world evidence studies, capturing treatment patterns, safety profiles, and patient-reported outcomes to inform clinical guidelines. His translational projects investigate molecular markers in tumor microenvironments, immune response modulation, and microbial colonization in chronic skin disease. Additionally, he has studied the dermatological manifestations of systemic diseases, including connective tissue disorders and HIV-associated conditions. With active roles in multicenter randomized controlled trials and investigator-initiated studies, Dr. Artosi is committed to bridging experimental science with practical dermatological care. His research goal is to develop therapeutic strategies that are both scientifically sound and clinically feasible, ultimately enhancing patient quality of life and long-term disease control.

Publications

Relationship between collagen disorders and hidradenitis suppurativa regarding two cases of Loeys-Dietz syndrome – European Journal of Pediatric Dermatology 
 A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients – Pharmaceuticals 
Mepolizumab induced palmoplantar psoriasis: A case report – World Journal of Clinical Cases 
Epidemiological and clinical analysis of exposure-related factors in non-melanoma skin cancer – Environmental Research 
Efficacy and safety of tildrakizumab in elderly patients – Journal of Dermatological Treatment 
Dermanyssus gallinae dermatitis in a young Italian woman – Italian Journal of Dermatology and Venereology 
Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin – Pharmaceuticals 
Apremilast as a Potential Targeted Therapy for Metabolic Syndrome in Psoriasis